Efficacy and tolerability of nebivolol: Does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I–II hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 6, Issue 5, 2012, Pages 185-199

  Germino, F Wilford ^a   Lin, Yuhua ^b   Bowen, Lynn ^b   Pejović, Vojislav ^c  

^a Orland Primary Care Specialists ^*  (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Prescott Medical Communications Group   (United States)

Author keywords

age groups; hypertension; nebivolol

Indexed keywords

NEBIVOLOL; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84867301940     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712459593     Document Type: Article

References (39)

1. Ambrosioni E. Borghi C. (2005) Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension: A meta-analysis. High Blood Press Cardiovasc Prev 12: 27–35.
2. Boydak B. Nalbantgil S. Fici F. Nalbantgil I. Zoghi M. Ozerkan F. et al. (2005) A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig 25: 409–416.
3. Briesacher B. Andrade S. Fouayzi H. Chan K. (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28: 437–443.
4. Brixius K. Middeke M. Lichtenthal A. Jahn E. Schwinger R. (2007) Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 34: 327–331.
5. Carlberg B. Nilsson P. (2010) Hypertension in the elderly: what is the goal blood pressure target and how can this be attained? Curr Hypertens Rep 12: 331–334.
6. Cleophas T. Grabowsky I. Niemeyer M. Makel W. van der Wall E. (2002) Paradoxical pressor effects of beta-blockers in standing elderly patients with mild hypertension: a beneficial side effect. Circulation 105: 1669–1671.
7. Cleophas T. van Marum R. (2003) Age-related decline in autonomic control of blood pressure: implications for the pharmacological management of hypertension in the elderly. Drugs Aging 20: 313–319.
8. Cordero A. Bertomeu-Martinez V. Mazon P. Facila L. Bertomeu-Gonzalez V. Con the P. et al. (2010) Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther 28: 15–22.
9. Cushman W. Ford C. Cutler J. Margolis K. Davis B. Grimm R. et al. (2002) Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4: 393–404.
10. Doumas M. Tsakiris A. Douma S. Grigorakis A. Papadopoulos A. Hounta A. et al. (2006) Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 8: 177–182.
11. Düsing R. (2005) Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 65: 773–786.
12. Egan B. Zhao Y. Axon R. (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303: 2043–2050.
13. Fischer M. Stedman M. Lii J. Vogeli C. Shrank W. Brookhart M. et al. (2010) Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 25: 284–290.
14. Fogari R. Zoppi A. (2004) Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 21: 377–393.
15. Fonseca V. (2010) Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 26: 615–629.
16. Forest Laboratories (2011) Bystolic: Full Prescribing Information. St Louis, MO: Forest Laboratories, Inc. Available at: http://www.frx.com/pi/Bystolic_pi.pdf.
17. Franklin S. Gustin W. Wong N. Larson M. Weber M. Kannel W. et al. (1997) Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 96: 308–315.
18. Franklin S. Jacobs M. Wong N. L'Italien G. Lapuerta P. (2001) Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37: 869–874.
19. Greathouse M. (2010) Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol 33 (4): E20–E27.
20. Howden L. Meyer J. (2011) 2010 Census briefs: Age and sex composition: 2010. Report no. C2010BR-03, US Census Bureau; US Department of Commerce. Available at: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf.
21. Kannel W. (2000) Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 85: 251–255.
22. Khan N. McAlister F. (2006) Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174: 1737–1742.
23. Ko D. Hebert P. Coffey C. Sedrakyan A. Curtis J. Krumholz H. (2002) Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 288: 351–357.
24. Ladage D. Reidenbach C. Rieckeheer E. Graf C. Schwinger R. Brixius K. (2010) Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol 56: 275–281.
25. Lyamina N. Dolotovskaya P. Lyamina S. Malyshev I. Manukhina E. (2003) Nitric oxide production and intensity of free radical processes in young men with high normal and hypertensive blood pressure. Med Sci Monit 9: 304–310.
26. McEniery C. Schmitt M. Qasem A. Webb D. Avolio A. Wilkinson I. et al. (2004) Nebivolol increases arterial distensibility in vivo. Hypertension 44: 305–310.
27. Messerli F. Grossman E. Goldbourt U. (1998) Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279: 1903–1907.
28. Münzel T. Gori T. (2009) Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 54: 1491–1499.
29. Paiva H. Kahonen M. Lehtimaki T. Raitakari O. Jula A. Viikari J. et al. (2008) Asymmetric dimethylarginine (ADMA) has a role in regulating systemic vascular tone in young healthy subjects: the cardiovascular risk in young Finns study. Am J Hypertens 21: 873–878.
30. Qureshi A. Suri M. Kirmani J. Divani A. (2005) Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 11: 403–409.
31. Safar M. (2010) Arterial aging - hemodynamic changes and therapeutic options. Nat Rev Cardiol 7: 442–449.
32. Saunders E. Smith W. de Salvo K. Sullivan W. (2007) The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 9: 866–875.
33. Shiri R. Koskimaki J. Hakkinen J. Auvinen A. Tammela T. Hakama M. (2007) Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 19: 208–212.
34. van Bortel L. Fici F. Mascagni F. (2008) Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 8: 35–44.
35. Vasan R. Beiser A. Seshadri S. Larson M. Kannel W. D'Agostino R. et al. (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287: 1003–1010.
36. Verhaeverbeke I. Mets T. (1997) Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 17: 105–118.
37. Weiss R. Saunders E. Greathouse M. (2011) Efficacy and tolerability of nebivolol in stage I–II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 33: 1150–1161.
38. Weiss R. Weber M. Carr A. Sullivan W. (2007) A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 9: 667–676.
39. World Health Organization (2009) Cardiovascular Diseases (CVDs). Fact Sheet No 317. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/print.html.